Buckingham Strategic Wealth’s Arbutus Biopharma ABUS Stock Holding History

Buckingham Strategic Wealth’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$55.1K	Buy	17,820 +100	+0.6%	+$300	﹤0.01%	751
2024 Q1	$45.7K	Hold	17,720	–	–	﹤0.01%	746
2023 Q4	$44.3K	Hold	17,720	–	–	﹤0.01%	713
2023 Q3	$36K	Hold	17,720	–	–	﹤0.01%	680
2023 Q2	$40.8K	Hold	17,720	–	–	﹤0.01%	682
2023 Q1	$41.3K	Hold	17,720	–	–	﹤0.01%	604
2022 Q4	$41.3K	Hold	17,720	–	–	﹤0.01%	606
2022 Q3	$34K	Sell	17,720 -11	-0.1%	-$26	﹤0.01%	592
2022 Q2	$48K	Buy	17,731 +11	+0.1%	+$28	﹤0.01%	587
2022 Q1	$53K	Buy	17,720 +5,000	+39%	+$15.3K	﹤0.01%	585
2021 Q4	$49K	Hold	12,720	–	–	﹤0.01%	588
2021 Q3	$55K	Buy	12,720 +1,000	+9%	+$3.33K	﹤0.01%	583
2021 Q2	$36K	Buy	+11,720	New	+$36.3K	﹤0.01%	585

Other funds holding ABUS

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

FCM

FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Buckingham Strategic Wealth's ABUS Position: Q2 2024 in Review

Buckingham Strategic Wealth increased its Arbutus Biopharma (ABUS) stake by 0.56% in Q2 2024, buying an estimated $300 and bringing the position to 17,820 shares worth $55.1K. The position accounts for ﹤0.01% of the portfolio, ranked #751.

Buckingham Strategic Wealth first reported a position in ABUS in Q2 2021 and has held it in 13 quarters since. 131 funds tracked by Wall St. Rank hold ABUS as of Q2 2024.

Buckingham Strategic Wealth held 17,820 shares of Arbutus Biopharma worth $55.1K as of Q2 2024.
Buckingham Strategic Wealth bought 100 Arbutus Biopharma shares in Q2 2024, an estimated $300.
Arbutus Biopharma made up ﹤0.01% of Buckingham Strategic Wealth's portfolio in Q2 2024, its #751 holding.
Buckingham Strategic Wealth first reported a position in Arbutus Biopharma in Q2 2021 and has held it in 13 quarters since.
131 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2024.

Based on Buckingham Strategic Wealth's 13F filing for Q2 2024, filed 12 Aug 2024.